Skip to search formSkip to main contentSkip to account menu

GSK 1838705A

Known as: GSK-1838705A, GSK1838705A 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrimidinesPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL
Anaplastic large cell lymphoma (ALCL) is a type of CD30-expressing non-Hodgkin's lymphoma (NHL), which accounts for 2% to 3% of… 
2018
2018
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1
Emerging evidence indicates that combining Sorafenib with vitamin K1 (VK1) may result in a synergistic inhibition of… 
2016
2016
Abstract 259: Modulation of doxorubicin actions on HCC cells by insulin-like growth factor-I
Tumor microenvironment is increasingly understood to influence tumor biology in many tumor types, including HCC. We recently… 
2015
2015
GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo
Glioma is a type of primary malignant tumor of the central nervous system in humans. At present, standard treatment involves… 
2015
2015
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
Blood platelet numbers are correlated with growth and aggressiveness of several tumor types, including hepatocellular carcinoma… 
2009
2009
Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors…
The insulin-like growth factor-1 receptor (IGF-1R) signaling pathway is activated in various tumors and inhibition of IGF-1R… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)